AZD2716

AZD2716 is a selective sPLA2 (secretory phospholipase A2) inhibitor. AZD2716 significantly reduces the production of pro-inflammatory lipids by inhibiting sPLA2-IIa (IC50 = 10 nM), sPLA2-V (IC50 = 40 nM), and sPLA2-X (IC50 = 400 nM), thereby decreasing macrophage activation and foam cell formation. AZD2716 is promising for studying mechanisms related to atherosclerosis and inflammatory diseases associated with sPLA2[1].

Product Specifications

CAS Number

1845753-81-2

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/azd2716.html

Purity

99.9

Solubility

DMSO : 10 mg/mL (ultrasonic; warming)

Smiles

NC(C1=C(C2=CC(C[C@@H](C)C(O)=O)=CC=C2)C=C(C=C1)CC3=CC=CC=C3)=O

Molecular Formula

C24H23NO3

Molecular Weight

373.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Karlsson S, et al. An enantioselective hydrogenation of an alkenoic acid as a key step in the synthesis of AZD2716[J]. Organic Process Research & Development, 2016, 20 (2) : 262-269.|[2]Giordanetto F, et al. Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease. ACS Med Chem Lett. 2016 Aug 9;7 (10) :884-889.